Finance Watch: Five Biopharma IPOs Bring US Total To 60 In 2021
Four To Go Public Via SPAC, Including Pardes Biosciences
Executive Summary
Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.
You may also be interested in...
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022
Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.
SPAC Mergers Take Biopharmas Public, But Valuations Often Sag Post-Closing
Merging with a special purpose acquisition corporation is a viable funding tool, but it may not be the best choice for drug developers far from key milestones.